Celltrion presented its future growth strategies and drug pipeline at the Morgan Stanley 22nd Annual Global Healthcare Conference, held in New York on September 6. During the event, CEO Seo Jin-seok outlined the company’s ambitious plans to expand its presence in biosimilars and innovate within antibody therapeutics, including the development of antibody-drug conjugates (ADC) and multi-antibody therapies.
Celltrion is actively working on three new ADC and multi-antibody drugs, with the first products expected by 2029. Two of the ADC candidates will enter clinical trials next year, signaling the company’s commitment to leading in this field. The company is also aiming to secure approval for 11 biosimilar products by 2025, increasing its portfolio to 22 by 2030.
Chairman Seo Jung-jin emphasized the success of Zimpentra in the U.S., which rapidly gained traction after its March launch, securing deals with key prescription drug benefit managers. With a media campaign set to boost visibility, Celltrion expects to hit its 2023 sales target of 250 billion won ($186.5 million). The company is confident of meeting its 3.5 trillion won sales target this year, with projections of up to 5 trillion won in 2024.
In addition, Seo revealed plans to expand manufacturing facilities, crucial for supporting Celltrion’s contract development and manufacturing organization (CDMO) operations. The final decision on new factory locations is expected by year-end.
